



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

SALE OF AN INDUSTRIAL SITE IN FRANCE

Brussels, 2nd September 2004 – UCB announced today the sale of its factory in Limay (Yvelines, France) to Nextpharma, who is a European leader in pharmaceutical manufacturing. This sale is part of the continuing process to optimize the efficiency of UCB manufacturing capacity.

The factory, which at present employs 105 people, specializes in the production of medicines mostly in the form of drinkable liquids (bottles and vials), creams, ointments and sprays.

No redundancies will result directly from this sale.

In addition, UCB Pharma France, where almost 500 people are employed, is one of the Group's most important pharmaceutical subsidiaries in Europe and it will go on growing.

About the UCB Group:

UCB (www.ucb-group.com) is a global pharmaceutical and specialty chemical leader with headquarters in Brussels, Belgium. UCB is focused on innovative solutions for human healthcare through its UCB Pharma division, as well as technically innovative products for surface applications through its Surface Specialities division, and employs 12,000 people around the world. UCB Pharma's research activities are focused in the fields of neurology, allergy and respiratory disease, inflammation and oncology. UCB Pharma's main products include Keppra (antiepileptic), Xyzal and Zyrtec (antiallergics), Nootropil (cerebral function regulator) and Tussionex (antitussive). UCB is listed on Euronext Brussels, and achieved sales of €3 billion and a net profit of €340 million in 2003.

Information:

UCB - Press contacts

Laurence Battaille
Head of Corporate Communication

Tel.: +32 (2) 559 95 88

UCB – Investor Relations contacts

Arnaud Denis
Investor Relations Manager

Tel.: +32 (2) 559 92 64

Brunswick

Jon Coles
Laurent Perpère

Tél. : +44 (0) 20 7404 5959

Tél. : +33 (1) 53 96 83 83